Get all premium features to the best stock analysis tool

iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript

Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET

Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference.

Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway

iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for a private placement ("PIPE") financing that is expected to result in gross proceeds of approximately $26 million to the Company before placement agent fees and offering expenses. The offering is expected to close on or about January 13, 2026, subject to customary closing conditions.